Crysvita
Crysvita ingredients
| Active ingredient | Strength |
|---|---|
| Burosumab | 20 mg/mL, 30 mg/mL, 10 mg/mL |
What Crysvita is used for
The FDA lists the approved uses on the official label (below). In the EU, burosumab is approved as Crysvita for:
Crysvita is indicated for the treatment of X-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. Crysvita is indicated for the treatment of FGF23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Crysvita
- Generic name
- Burosumab
- Made by
- Kyowa Kirin, Inc.
- Forms
- Injection
- Given
- Subcutaneous
- FDA approval
- Biologic licence (BLA) BLA761068
- On the US market since
- 2018
Official information
- Crysvita prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Burosumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Crysvita?
Crysvita (Burosumab) is a specialist medicine made by Kyowa Kirin, Inc., approved by the US FDA.
What are the ingredients of Crysvita?
Crysvita contains Burosumab (20 mg/mL, 30 mg/mL, 10 mg/mL).
Is Crysvita approved in Europe?
The same active substance is approved in the EU as Crysvita.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA